Parkinson’s Disease

Research Article

Programming for Stimulation-Induced Transient Nonmotor Psychiatric Symptoms after Bilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease

Table 1

(a) Baseline clinical data of patients who developed STPS.


	Age	Gender	Duration (year)	MMSE	HAMD ()	LEDD pre-op (mg)	LEED STPS Emerged	LEDD 3 m post-STPS (mg)	UPDRS I	UPDRS II	UPDRS-III		UPDRS IV
	Age	Gender	Duration (year)	MMSE	HAMD ()	LEDD pre-op (mg)	LEED STPS Emerged	LEDD 3 m post-STPS (mg)	UPDRS I	UPDRS II	Pre-op med-off	Pre-op med-on	UPDRS IV

PD1	61	M	17	29	19 (14)	1200	1200	550	8	17	47	13	3
PD2	52	M	14	29	10	900	125	125	4	18	41	15	6
PD3	59	F	8	30	21 (16)	768	325	300	7	24	53	26	9
PD4	74	M	7	26	10	563	175	175	6	31	37	24	11
PD5	61	M	8	29	17 (10)	825	825	280	5	11	43	15	10
PD6	58	M	11	26	30 (17)	1100	325	325	10	18	75	42	4
PD7	52	F	15	27	11	963	75	75	2	13	70	34	3
PD8	75	F	13	27	16	1287	300	200	4	20	81	37	8
PD9	72	F	10	28	8	787	250	250	4	13	27	16	4
PD10	64	F	13	26	24 (13)	750	150	150	5	16	51	28	7
PD11	70	F	15	27	30 (16)	1225	700	700	9	22	63	31	10

α: post-antidepression treatment; LEDD: Levodopa Equivalent Daily Dose.

(b) Compare the baseline data of STPS positive Versus STPS negative patients.


	STPS+	STPS−	value

Patient	11	443
Age	63.45 ± 8.28	62.05 ± 7.78	0.555
Disease duration to DBS	11.91 ± 3.33	9.95 ± 4.03	0.112
LEDD pre-op (mg)	942.55 ± 232.67	836.32 ± 393.79	0.374
UPDRS-III med-off pre-op	53.45 ± 16.94	52.46 ± 14.24	0.819
UPDRS-III med-on pre-op	25.55 ± 9.91	25.80 ± 11.14	0.940
MMSE	27.64 ± 1.43	27.07 ± 2.57	0.463
HAMD before receiving antidepressant drug	17.82 ± 7.85	20.71 ± 6.21	0.130

: 443 patients included three groups: 145 patients initiated the IPG and 99 of them achieved the optimal programming parameters before the study was finished; the 99 patients and other 132 patient who achieved the optimal programming parameters received STN-DBS for less than one year. 166 patients had received STN-DBS for more than one year: 145 + 132 + 166 = 443.